Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

Artigo Acesso aberto Revisado por pares

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

2013; Lippincott Williams & Wilkins; Volume: 31; Issue: 26 Linguagem: Inglês

10.1200/jco.2012.48.3990

ISSN

1527-7755

Autores

Brian K. Link, Matthew J. Maurer, Grzegorz S. Nowakowski, Stephen M. Ansell, William R. Macon, Sergei Syrbu, Susan L. Slager, Carrie A. Thompson, David J. Inwards, Patrick B. Johnston, Joseph P. Colgan, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource